BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 2019;3:3248-60. [PMID: 31698455 DOI: 10.1182/bloodadvances.2019000703] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Li LZ, Zhang Z, Bhoj VG. Conventional T cell therapies pave the way for novel Treg therapeutics. Cell Immunol 2021;359:104234. [PMID: 33153708 DOI: 10.1016/j.cellimm.2020.104234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. The antigen-binding moiety in the driver's seat of CARs. Med Res Rev 2021. [PMID: 34028069 DOI: 10.1002/med.21818] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Xu S, Lam KP. Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma? Cancers (Basel) 2020;12:E1045. [PMID: 32340409 DOI: 10.3390/cancers12041045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 2021;27:1419-31. [PMID: 34312556 DOI: 10.1038/s41591-021-01436-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 van der Schans JJ, van de Donk NWCJ, Mutis T. Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. Front Oncol 2020;10:1362. [PMID: 32850436 DOI: 10.3389/fonc.2020.01362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 . CRISPR Meets Proteomics: How IsoPlexis' Single Cell Data is Revolutionizing Therapeutic Genome Editing. CRISPR J 2020;3:233-6. [PMID: 32833538 DOI: 10.1089/crispr.2020.29099.iso] [Reference Citation Analysis]
7 Lindo L, Wilkinson LH, Hay KA. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. Front Immunol 2020;11:618387. [PMID: 33643299 DOI: 10.3389/fimmu.2020.618387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 García-Guerrero E, Sierro-Martínez B, Pérez-Simón JA. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Front Immunol 2020;11:1128. [PMID: 32582204 DOI: 10.3389/fimmu.2020.01128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in Multiple Myeloma. Cells 2020;9:E601. [PMID: 32138182 DOI: 10.3390/cells9030601] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
10 Fang Y, Hou J. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. Mil Med Res 2021;8:9. [PMID: 33504363 DOI: 10.1186/s40779-021-00302-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 2021;21:145-61. [PMID: 33483715 DOI: 10.1038/s41568-020-00323-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
12 Beyar-Katz O, Gill S. Advances in chimeric antigen receptor T cells.Curr Opin Hematol. 2020;27:368-377. [PMID: 32925186 DOI: 10.1097/MOH.0000000000000614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
13 Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Scand J Immunol 2020;92:e12910. [PMID: 32471019 DOI: 10.1111/sji.12910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Sircar A, Chowdhury SM, Hart A, Bell WC, Singh S, Sehgal L, Epperla N. Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. Int J Mol Sci 2020;21:E904. [PMID: 32019190 DOI: 10.3390/ijms21030904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
15 Qi J, Guo Y, Huang H, Yao J, Xu L, Ju S, Li X. Decellularized ECM derived from normal bone involved in the viability and chemo-sensitivity in multiple myeloma cells. Exp Cell Res 2021;408:112870. [PMID: 34648843 DOI: 10.1016/j.yexcr.2021.112870] [Reference Citation Analysis]
16 Dubrot J, Lane-Reticker SK, Kessler EA, Ayer A, Mishra G, Wolfe CH, Zimmer MD, Du PP, Mahapatra A, Ockerman KM, Davis TGR, Kohnle IC, Pope HW, Allen PM, Olander KE, Iracheta-Vellve A, Doench JG, Haining WN, Yates KB, Manguso RT. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity 2021;54:571-585.e6. [PMID: 33497609 DOI: 10.1016/j.immuni.2021.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
17 Hosen N. Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Cancers (Basel). 2019;11:2024. [PMID: 31847470 DOI: 10.3390/cancers11122024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T, Abildgaard N. Harnessing the Immune System to Fight Multiple Myeloma. Cancers (Basel) 2021;13:4546. [PMID: 34572773 DOI: 10.3390/cancers13184546] [Reference Citation Analysis]
19 Wang J, Yang J, Kopeček J. Nanomedicines in B cell-targeting therapies. Acta Biomater 2021:S1742-7061(21)00692-9. [PMID: 34687954 DOI: 10.1016/j.actbio.2021.10.024] [Reference Citation Analysis]
20 van de Donk NWCJ, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov 2021;2:302-18. [PMID: 34386775 DOI: 10.1158/2643-3230.bcd-20-0227] [Reference Citation Analysis]
21 Tan X, Letendre JH, Collins JJ, Wong WW. Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. Cell 2021;184:881-98. [PMID: 33571426 DOI: 10.1016/j.cell.2021.01.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
22 Nassar SF, Raddassi K, Wu T. Single-Cell Multiomics Analysis for Drug Discovery. Metabolites 2021;11:729. [PMID: 34822387 DOI: 10.3390/metabo11110729] [Reference Citation Analysis]
23 Zhang L, Wang Y, Xu KL. [Mechanisms and prevention strategies of relapse and resistance after BCMA-CAR-T cell in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2021;42:778-81. [PMID: 34753237 DOI: 10.3760/cma.j.issn.0253-2727.2021.09.014] [Reference Citation Analysis]
24 Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai YT. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 2021;35:752-63. [PMID: 32632095 DOI: 10.1038/s41375-020-0951-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
25 Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer 2020;8:e000990. [PMID: 32900862 DOI: 10.1136/jitc-2020-000990] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 2021;11:84. [PMID: 33927192 DOI: 10.1038/s41408-021-00469-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
27 Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther 2021:S2666-6367(21)00946-5. [PMID: 34107340 DOI: 10.1016/j.jtct.2021.05.027] [Reference Citation Analysis]
28 Ti D, Bai M, Li X, Wei J, Chen D, Wu Z, Wang Y, Han W. Adaptive T cell immunotherapy in cancer. Sci China Life Sci 2021;64:363-71. [PMID: 32712831 DOI: 10.1007/s11427-020-1713-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Liu H, Pan C, Song W, Liu D, Li Z, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res 2021;9:62. [PMID: 34332618 DOI: 10.1186/s40364-021-00316-6] [Reference Citation Analysis]
30 Zeng W, Zhang P. Resistance and recurrence of malignancies after CAR-T cell therapy. Exp Cell Res 2022;410:112971. [PMID: 34906583 DOI: 10.1016/j.yexcr.2021.112971] [Reference Citation Analysis]
31 Atrash S, Moyo TK. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. Onco Targets Ther 2021;14:2185-201. [PMID: 33814917 DOI: 10.2147/OTT.S242018] [Reference Citation Analysis]
32 Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer 2021;9:e003354. [PMID: 34706886 DOI: 10.1136/jitc-2021-003354] [Reference Citation Analysis]
33 Weber EW, Maus MV, Mackall CL. The Emerging Landscape of Immune Cell Therapies. Cell 2020;181:46-62. [PMID: 32243795 DOI: 10.1016/j.cell.2020.03.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 30.5] [Reference Citation Analysis]
34 Nicolini F, Bravaccini S, Mazza M, Gruszka AM, Tazzari M, MartÍn-Antonio B, Juan M, Ibrahim T, Maltoni R, Martinelli G, Cerchione C. CAR T cells targeting options in the fight against multiple myeloma. Panminerva Med 2021;63:37-45. [PMID: 32955187 DOI: 10.23736/S0031-0808.20.04146-4] [Reference Citation Analysis]
35 Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest 2020;130:1586-94. [PMID: 32235098 DOI: 10.1172/JCI129208] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 12.5] [Reference Citation Analysis]
36 Oriol A, Abril L, Torrent A, Ibarra G, Ribera JM. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Ther Adv Hematol 2021;12:20406207211019622. [PMID: 34104374 DOI: 10.1177/20406207211019622] [Reference Citation Analysis]
37 Wehrli M, Maus MV. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Curr Opin Pharmacol 2021;59:116-26. [PMID: 34198161 DOI: 10.1016/j.coph.2021.05.005] [Reference Citation Analysis]